ReviewParkinson's disease2021
Lee Silverman Voice Treatment to Improve Speech in Parkinson's Disease: A Systemic Review and Meta-Analysis.
Review in Parkinson's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Baseline predictors of response to a group-based speech and communication intervention in Parkinson's disease: A secondary analysis of a randomized controlled trial.Journal of Parkinson's disease · 2026Trial
- Comparing face-to-face and online LSVT®LOUD speech training using LSVT®Coach in patients with Parkinson's disease: a pilot randomised controlled trial.BMC neurology · 2025Trial
- The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT.Health technology assessment (Winchester, England) · 2024Trial
- Parkinson's Disease Multidisciplinary Complex Therapy (PD-MCT): appreciation of its current function for the treatment of people with Parkinson's disease in Germany and the needs of future development.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- To Treat or Not to Treat: A Scoping Review of Speech Treatment for Dysarthria in Amyotrophic Lateral Sclerosis (ALS).Healthcare (Basel, Switzerland) · 2025Review
- The Role of Laryngology Evaluation in Parkinson Dysphonia Therapy: Process Evaluation and Outcomes.Journal of voice : official journal of the Voice Foundation · 2025Article
- Exploring Speech and Language Therapists' Perspectives of Voice-Assisted Technology as a Tool for Dysarthria: Qualitative Study.JMIR rehabilitation and assistive technologies · 2025Article
- Healthcare Complexities in Neurodegenerative Proteinopathies: A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- Prevalence and Treatment of Dysphonia in Parkinson's Disease: A Cross-Sectional National Database Study.Laryngoscope investigative otolaryngology · 2025Article
- Voice Meets Swallowing: A Scoping Review of Therapeutic Connections.American journal of speech-language pathology · 2025Article
- Article
- Breaking barriers in Parkinson's care: the multidisciplinary team approach.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Unveiling early signs of Parkinson's disease via a longitudinal analysis of celebrity speech recordings.NPJ Parkinson's disease · 2024Article
- Effectiveness of remotely delivered speech therapy in persons with Parkinson's disease - a randomised controlled trial.EClinicalMedicine · 2024Article
- Contributions of Speech Timing and Articulatory Precision to Listener Perceptions of Intelligibility and Naturalness in Parkinson's Disease.Journal of speech, language, and hearing research : JSLHR · 2024Article
- Specialized Allied Health Care for Parkinson's Disease: State of the Art and Future Directions.Journal of Parkinson's disease · 2024Review
- Speech and neuroimaging effects following HiCommunication: a randomized controlled group intervention trial in Parkinson's disease.Brain communications · 2024Article
- A Communication Partner Training Program Delivered via Telehealth for People Living With Parkinson's (Better Conversations With Parkinson's): Protocol for a Feasibility Study.JMIR research protocols · 2023Article
- Multidimensional voice assessment after Lee Silverman Voice Therapy (LSVTActa otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2022Article
- Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study.Movement disorders : official journal of the Movement Disorder Society · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpeech changes occur in the early stages of Parkinson's disease (PD) and cause communication difficulties, leading to social isolation. Lee Silverman voice treatment (LSVT) is a speech therapy approach designed to improve patients' language and voice capabilities.
objectiveThe effectiveness of the LSVT was compared with that of other speech interventions or no treatment to evaluate PD patients with dysarthria.
designSystematic review with meta-analysis of randomized trials.
methodAbstracts were screened and reviewed against the eligibility criteria (intervention group participants were PD assessed based on LSVT (LSVT Loud) and randomized control).
resultTen randomized controlled trials were identified on speech symptoms in patients with PD. Compared with the respiratory therapy (RET) exercise, or no training group, a significant improvement was detected in the sound press level (SPL) after immediate treatment during the reading of vowel and rainbow passages and an increase in semitone standard deviation (STSD). Furthermore, the LSVT training significantly increased the participants' scores on unified Parkinson's disease rating scale (UPDRS-III) and speech intelligibility.
conclusionThis meta-analysis demonstrated the efficacy of LSVT in increasing vocal loudness and functional communication among individuals with PD. However, most studies included participants with mild-moderate PD. Thus, additional randomized controlled trials (RCTs) with large sample sizes are needed to validate the efficacy of LSVT in patients with different progressions of PD, including severe PD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.